Catalyst Pharmaceuticals Gross Profit

Catalyst Pharmaceuticals (CPRX) currently reports a gross profit of $510M as of March 2026. That compares with $440M in the prior-year period — up 15.2% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Catalyst Pharmaceuticals's gross profit history and peer comparisons.

Catalyst Pharmaceuticals's gross profit increased from $440M to $510M — a 15.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Catalyst Pharmaceuticals's gross profit of $510M is lower than the Healthcare sector average of $67B. That is roughly 99.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Catalyst Pharmaceuticals reported $510M in gross profit as of March 2026. That compares with $440M in the prior-year period — up 15.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $510M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Catalyst Pharmaceuticals, and consider following CPRX for alerts when major investors trade the stock.